2014

New FDA-sponsored research: National and international device registries needed

Thursday, December 18, 2014

Most Americans will be exposed to a medical device during their lives and tens of millions will receive an implantable device. However, public health and regulatory agencies in the U.S. and internationally acknowledge there are gaps both in the ability to track these devices and to provide the public the accurate, evidence-based information consumers need to improve their health and make informed care decisions.

[Read More]

Research, generic/biosimilar industries call for integrated strategy for Europe

Thursday, December 18, 2014

Ahead of the adoption of the European Commission Work Program, the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Generic Medicines Association (EGA) have reiterated their joint Europe 2020 strategy submission for an industrial policy for the globalization era and the value it places in the pharmaceutical sector. The joint submission highlights key proposals on how to successfully integrate the pharmaceutical sector for an industrial policy that will boost European health and wealth alike.

[Read More]

Survey: France Biotech recommends policies to develop innovative life sciences companies

Thursday, December 18, 2014

France Biotech, an association of entrepreneurs in the life sciences industry, has published the twelfth edition of its annual survey, Panorama of the Life Sciences Industry, which outlines the industry’s major trends for 2013 and 2014 in France and worldwide. This year, 214 French companies took part in the study. France Biotech included multiple recommendations to foster excellence in the life sciences industry.

[Read More]

FDA announces Pharmacy Compounding Advisory Committee members

Wednesday, December 17, 2014

The FDA has announced the membership of the Pharmacy Compounding Advisory Committee. The committee is comprised of 14 members—12 voting and two non-voting—who will provide advice on scientific, technical and medical issues concerning drug compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

[Read More]